Related Experiment Video

Updated: Dec 9, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.1K

A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand

Vincenzo De Sanctis1, Duran Canatan2, Joan Lluis Vives Corrons3

  • 1Quisisana Hospital, Ferrara. vdesanctis@libero.it.

Acta Bio-Medica : Atenei Parmensis
|September 14, 2020
PubMed

Insights

COVID-19 appears less common in beta-thalassemia patients, but co-morbidities worsen outcomes. A multicenter registry is needed for better COVID-19 management in thalassemia.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Public Health

Background:

  • Thalassemia is a group of inherited blood disorders.
  • The COVID-19 pandemic has impacted global health.
  • Understanding COVID-19's effect on vulnerable populations like thalassemia patients is crucial.

Purpose of the Study:

  • To review the existing literature on COVID-19 in patients with thalassemia.
  • To identify trends in prevalence, severity, and outcomes.
  • To highlight the need for further research and improved management strategies.

Main Methods:

  • Literature review of studies on COVID-19 in thalassemia patients.
  • Analysis of reported prevalence, co-morbidities, and prognosis.
  • Synthesis of findings to inform clinical practice.

Main Results:

  • Global prevalence of COVID-19 in beta-thalassemia patients appears lower than in the general population.
  • Associated co-morbidities significantly aggravate COVID-19 severity and lead to poorer prognosis.
  • Age is not a determining factor in COVID-19 prognosis for these patients.

Conclusions:

  • Further research, including multicenter registries, is essential to better understand COVID-19 in thalassemia.
  • Evidence-based management recommendations are needed for this patient group.
  • Co-morbidities are key determinants of COVID-19 severity and outcomes in thalassemia patients.

More Related Videos

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.1K

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.6K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.9K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
375
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
623
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
380
Tertiary Healthcare System01:21

Tertiary Healthcare System

Specialized care provided over an extended period is called tertiary care. Usually, a primary or secondary care physician will refer a patient to tertiary care. A patient's maximum physical and mental function is restored in tertiary care, which is caused due to the impact of a chronic illness or condition. Tertiary care aims to achieve the highest level of functioning possible while managing chronic illness. For example, a patient who falls and fractures their hip will need secondary care...
2.0K